Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: Report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour

Pathology

Volumn 38, Issue 6, 2006, Pages 534-538

  Stewart, Colin J R ^a   Tsukamoto, Tetsuya ^c   Cooke, Bridget ^b   Leung, Yee C ^a   Hammond, Ian G ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b ST JOHN OF GOD HOSPITAL   (Australia)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Immunohistochemistry; Mucinous tumour; Ovary; Pseudomyxoma peritonei; Teratoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; MUCIN 2; MUCIN 5AC; MUCIN 6; TRANSCRIPTION FACTOR CDX2; CDX 2 3 PROTEIN; CDX-2-3 PROTEIN; HOMEODOMAIN PROTEIN; MUC 2 PROTEIN; MUCIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL HYSTERECTOMY; ADULT; ANTIGEN EXPRESSION; APPENDECTOMY; APPENDIX TUMOR; ARTICLE; ASCITES FLUID; CANCER PATIENT; CASE REPORT; CHOLECYSTECTOMY; CYTOLOGY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; OVARY TERATOMA; OVARY TUMOR; PERITONEUM PSEUDOMYXOMA; PHENOTYPE; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY; TUMOR VOLUME; COLLOID CARCINOMA; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; TERATOMA;

ADENOCARCINOMA, MUCINOUS; ADULT; APPENDICEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MIDDLE AGED; MUCINS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PSEUDOMYXOMA PERITONEI; TERATOMA; TRANS-ACTIVATORS;

EID: 34247167642     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020601024078     Document Type: Article

References (31)

1. Young RH. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. Semin Diagn Pathol 2004; 21: 134-50.
2. Pai RK, Longacre TA. Appendiceal mucinous tumors and pseudomyxoma peritonei. Histologic features, diagnostic problems, and proposed classification. Adv Anat Pathol 2005; 12: 291-311.
3. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 2005; 123: S13-57.
4. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with "pseudomyxoma peritonei". Am J Surg Pathol 2000; 24: 1447-64.
5. McKenna JC, Soslow RA, Longacre TA. Mucinous neoplasms arising in mature cystic teratomas: a clinicopathologic study of ovarian and sacrococcygeal tumors. Mod Pathol 2004; 17: 206A.
6. Tang P, Soukkary S, Kahn E. Mature cystic teratoma of the ovary associated with complete colonic wall and mucinous cystadenoma. Ann Clin Lab Sci 2003; 33: 465-70.
7. Hunter V, Barnhill D, Jadwin D, et al. Ovarian mucinous cystadenocarcinoma of low malignant potential associated with a mature cystic teratoma. Gynecol Oncol 1988; 29: 250-4.
8. Fishman A, Edelstein. , E, Altaras M, et al. Adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary. Gynecol Oncol 1998; 70: 418-20.
9. Fujiwara K, Ginzan S, Silverberg SG. Mature cystic teratomas of the ovary with intestinal wall structures harbouring intestinal-type epithelial neoplasms. Gynecol Oncol 1995; 56: 97-101.
10. Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas. Relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol 2003; 27: 650-7.
11. Pranesh N, Menasce LP, Wilson MS, et al. Pseudomyxoma peritonei: unusual origin from an ovarian mature cystic teratoma. J Clin Pathol 2005; 58: 1115-7.
12. Tsukamoto T, Mizoshita T, Mihara M, et al. Sox2 expression in human stomach adenocarcinomas with gastric and gastric-andintestinal-mixed phenotypes. Histopathology 2005; 46: 649-58.
13. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms. A clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27: 1089-103.
14. McCluggage WG. Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol 2006; 25: 101-20.
15. Yajima N, Wada R, Yamagishi S, et al. Immunohistochemical expressions of cytokeratins, mucin core proteins, p53, and neuroendocrine cell markers in epithelial neoplasm of appendix. Hum Pathol 2005; 36: 1217-25.
16. Guerrieri C, Franlund B, Fristedt S, et al. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum Pathol 1997; 28: 1039-45.
17. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998; 29: 491-7.
18. Wauters CCAP, Smedts F, Gerrits LGM, et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995; 26: 852-5.
19. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002; 21: 391-400.
20. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002; 117: 944-51.
21. Raspollini MR, Amunni G, Villanucci A, et al. Utilitiy of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma. An immunohistochemical comparison of 43 cases. Appl Immunohistochem Mol Morphol 2004; 12: 127-31.
22. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996; 9: 426-9.
23. Groisman GM, Meir A, Sabo E. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol 2004; 23: 52-7.
24. Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Koren Med Sci 2005; 20: 643-8.
25. Albarracin CT, Jafri J, Montag AG, et al. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Hum Pathol 2000; 31: 672-7.
26. Tornillo L, Moch H, Diener P-A, et al. CDX-2 immunostaining in primary and secondary ovarian carcinomas. J Clin Pathol 2004; 57: 641-3.
27. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003; 27: 303-10.
28. Fragetta F, Pelosi G, Cafici A, et al. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch 2003; 443: 782-6.
29. Hanski C, Hofmeier M, Schmitt-Graff A, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 1997; 182: 385-91.
30. Boman F, Buisine MP, Wacrenier A, et al. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridisation study. J Pathol 2001; 193: 339-44.
31. O'Connell JT, Tomlinson JS, Roberts AA, et al. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol 2002; 161: 551-64.